The improvement of neurodegenerative condition affects a lot more than 35 million people worldwide . The research team at the University of Sydney’s Brain and Brain Analysis Institute was led by Associate Professor Lars Ittner, from the Alzheimer’s and Parkinson’s disease Laboratory. Related StoriesAnalyzing potential TB vaccineNew study may offer approaches for developing toxoplasma-inactivated vaccineNew vaccine candidate shows great guarantee at fighting respiratory syncytial virusThe vaccine, which targets a broken protein inside brain’s nerve cell known as tau, prevents the ongoing neurofibrillary tangles in the mind of a mouse with Alzheimer’s disease.

Alzheimer’s medication pioneer to be awarded Israel Prize for Medicine Prof. Marta Weinstock-Rosin created blockbuster medication Exelon at Hebrew University's School of Pharmacy Israel's Minister of Education Shai Piron has announced that the Israel Prize for Medication will be awarded to the Hebrew University of Jerusalem's Prof. Marta Weinstock-Rosin. A professor emeritus at the Hebrew University's School of Pharmacy-Institute for Medication Research in the Faculty of Medication, Weinstock-Rosin is best known for developing Exelon, a blockbuster drug for the treating confusion and dementia linked to Alzheimer's and Parkinson's illnesses. Related StoriesEight myths and truths about Alzheimer's diseaseAdvances entirely mount human brain imaging: an interview with Patrick Myles, President, Huron Digital PathologyRestoring memory space in aging mice Weinstock-Rosin is married with four kids and 20 grandchildren.